293 related articles for article (PubMed ID: 24667985)
1. Targeting inhibitors of the tumor suppressor PP2A for the treatment of pancreatic cancer.
Farrell AS; Allen-Petersen B; Daniel CJ; Wang X; Wang Z; Rodriguez S; Impey S; Oddo J; Vitek MP; Lopez C; Christensen DJ; Sheppard B; Sears RC
Mol Cancer Res; 2014 Jun; 12(6):924-39. PubMed ID: 24667985
[TBL] [Abstract][Full Text] [Related]
2. Targeting c-MYC by antagonizing PP2A inhibitors in breast cancer.
Janghorban M; Farrell AS; Allen-Petersen BL; Pelz C; Daniel CJ; Oddo J; Langer EM; Christensen DJ; Sears RC
Proc Natl Acad Sci U S A; 2014 Jun; 111(25):9157-62. PubMed ID: 24927563
[TBL] [Abstract][Full Text] [Related]
3. The concept of the okadaic acid class of tumor promoters is revived in endogenous protein inhibitors of protein phosphatase 2A, SET and CIP2A, in human cancers.
Fujiki H; Sueoka E; Watanabe T; Suganuma M
J Cancer Res Clin Oncol; 2018 Dec; 144(12):2339-2349. PubMed ID: 30341686
[TBL] [Abstract][Full Text] [Related]
4. Targeting SET to restore PP2A activity disrupts an oncogenic CIP2A-feedforward loop and impairs triple negative breast cancer progression.
Liu CY; Huang TT; Chen YT; Chen JL; Chu PY; Huang CT; Wang WL; Lau KY; Dai MS; Shiau CW; Tseng LM
EBioMedicine; 2019 Feb; 40():263-275. PubMed ID: 30651219
[TBL] [Abstract][Full Text] [Related]
5. Antagonism of SET using OP449 enhances the efficacy of tyrosine kinase inhibitors and overcomes drug resistance in myeloid leukemia.
Agarwal A; MacKenzie RJ; Pippa R; Eide CA; Oddo J; Tyner JW; Sears R; Vitek MP; Odero MD; Christensen DJ; Druker BJ
Clin Cancer Res; 2014 Apr; 20(8):2092-103. PubMed ID: 24436473
[TBL] [Abstract][Full Text] [Related]
6. Sphingosine analogue drug FTY720 targets I2PP2A/SET and mediates lung tumour suppression via activation of PP2A-RIPK1-dependent necroptosis.
Saddoughi SA; Gencer S; Peterson YK; Ward KE; Mukhopadhyay A; Oaks J; Bielawski J; Szulc ZM; Thomas RJ; Selvam SP; Senkal CE; Garrett-Mayer E; De Palma RM; Fedarovich D; Liu A; Habib AA; Stahelin RV; Perrotti D; Ogretmen B
EMBO Mol Med; 2013 Jan; 5(1):105-21. PubMed ID: 23180565
[TBL] [Abstract][Full Text] [Related]
7. Combined targeting of SET and tyrosine kinases provides an effective therapeutic approach in human T-cell acute lymphoblastic leukemia.
Richard NP; Pippa R; Cleary MM; Puri A; Tibbitts D; Mahmood S; Christensen DJ; Jeng S; McWeeney S; Look AT; Chang BH; Tyner JW; Vitek MP; Odero MD; Sears R; Agarwal A
Oncotarget; 2016 Dec; 7(51):84214-84227. PubMed ID: 27705940
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of Pten deficient Castration Resistant Prostate Cancer by Targeting of the SET - PP2A Signaling axis.
Hu X; Garcia C; Fazli L; Gleave M; Vitek MP; Jansen M; Christensen D; Mulholland DJ
Sci Rep; 2015 Nov; 5():15182. PubMed ID: 26563471
[TBL] [Abstract][Full Text] [Related]
9. The therapeutic effects of SET/I2PP2A inhibitors on canine melanoma.
Enjoji S; Yabe R; Fujiwara N; Tsuji S; Vitek MP; Mizuno T; Nakagawa T; Usui T; Ohama T; Sato K
J Vet Med Sci; 2015 Nov; 77(11):1451-6. PubMed ID: 26062569
[TBL] [Abstract][Full Text] [Related]
10. PP2A inhibition is a common event in colorectal cancer and its restoration using FTY720 shows promising therapeutic potential.
Cristóbal I; Manso R; Rincón R; Caramés C; Senin C; Borrero A; Martínez-Useros J; Rodriguez M; Zazo S; Aguilera O; Madoz-Gúrpide J; Rojo F; García-Foncillas J
Mol Cancer Ther; 2014 Apr; 13(4):938-47. PubMed ID: 24448818
[TBL] [Abstract][Full Text] [Related]
11. Phosphoproteome and drug-response effects mediated by the three protein phosphatase 2A inhibitor proteins CIP2A, SET, and PME-1.
Kauko O; Imanishi SY; Kulesskiy E; Yetukuri L; Laajala TD; Sharma M; Pavic K; Aakula A; Rupp C; Jumppanen M; Haapaniemi P; Ruan L; Yadav B; Suni V; Varila T; Corthals GL; Reimand J; Wennerberg K; Aittokallio T; Westermarck J
J Biol Chem; 2020 Mar; 295(13):4194-4211. PubMed ID: 32071079
[TBL] [Abstract][Full Text] [Related]
12. Overexpression of PP2A inhibitor SET oncoprotein is associated with tumor progression and poor prognosis in human non-small cell lung cancer.
Liu H; Gu Y; Wang H; Yin J; Zheng G; Zhang Z; Lu M; Wang C; He Z
Oncotarget; 2015 Jun; 6(17):14913-25. PubMed ID: 25945834
[TBL] [Abstract][Full Text] [Related]
13. PP2A inhibition as a novel therapeutic target in castration-resistant prostate cancer.
González-Alonso P; Cristóbal I; Manso R; Madoz-Gúrpide J; García-Foncillas J; Rojo F
Tumour Biol; 2015 Aug; 36(8):5753-5. PubMed ID: 26234767
[TBL] [Abstract][Full Text] [Related]
14. The interaction of SET and protein phosphatase 2A as target for cancer therapy.
Dacol EC; Wang S; Chen Y; Lepique AP
Biochim Biophys Acta Rev Cancer; 2021 Aug; 1876(1):188578. PubMed ID: 34116173
[TBL] [Abstract][Full Text] [Related]
15. Targeting SET/I(2)PP2A oncoprotein functions as a multi-pathway strategy for cancer therapy.
Switzer CH; Cheng RY; Vitek TM; Christensen DJ; Wink DA; Vitek MP
Oncogene; 2011 Jun; 30(22):2504-13. PubMed ID: 21297667
[TBL] [Abstract][Full Text] [Related]
16. Targeting inhibitor 2 of protein phosphatase 2A as a therapeutic strategy for prostate cancer treatment.
Mukhopadhyay A; Tabanor K; Chaguturu R; Aldrich JV
Cancer Biol Ther; 2013 Oct; 14(10):962-72. PubMed ID: 24025258
[TBL] [Abstract][Full Text] [Related]
17. Chk1 targeting reactivates PP2A tumor suppressor activity in cancer cells.
Khanna A; Kauko O; Böckelman C; Laine A; Schreck I; Partanen JI; Szwajda A; Bormann S; Bilgen T; Helenius M; Pokharel YR; Pimanda J; Russel MR; Haglund C; Cole KA; Klefström J; Aittokallio T; Weiss C; Ristimäki A; Visakorpi T; Westermarck J
Cancer Res; 2013 Nov; 73(22):6757-69. PubMed ID: 24072747
[TBL] [Abstract][Full Text] [Related]
18. Stemness Is Enhanced in Gastric Cancer by a SET/PP2A/E2F1 Axis.
Enjoji S; Yabe R; Tsuji S; Yoshimura K; Kawasaki H; Sakurai M; Sakai Y; Takenouchi H; Yoshino S; Hazama S; Nagano H; Oshima H; Oshima M; Vitek MP; Matsuura T; Hippo Y; Usui T; Ohama T; Sato K
Mol Cancer Res; 2018 Mar; 16(3):554-563. PubMed ID: 29330298
[TBL] [Abstract][Full Text] [Related]
19. PP2A inhibitor SET promotes mTORC1 and Bmi1 signaling through Akt activation and maintains the colony-formation ability of cancer cells.
Kohyanagi N; Kitamura N; Ikeda S; Shibutani S; Sato K; Ohama T
J Biol Chem; 2024 Jan; 300(1):105584. PubMed ID: 38141761
[TBL] [Abstract][Full Text] [Related]
20. Potential role for inhibition of protein phosphatase 2A tumor suppressor in salivary gland malignancies.
Routila J; Mäkelä JA; Luukkaa H; Leivo I; Irjala H; Westermarck J; Mäkitie A; Ventelä S
Genes Chromosomes Cancer; 2016 Jan; 55(1):69-81. PubMed ID: 26395031
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]